<code id='45D2B7F1DC'></code><style id='45D2B7F1DC'></style>
    • <acronym id='45D2B7F1DC'></acronym>
      <center id='45D2B7F1DC'><center id='45D2B7F1DC'><tfoot id='45D2B7F1DC'></tfoot></center><abbr id='45D2B7F1DC'><dir id='45D2B7F1DC'><tfoot id='45D2B7F1DC'></tfoot><noframes id='45D2B7F1DC'>

    • <optgroup id='45D2B7F1DC'><strike id='45D2B7F1DC'><sup id='45D2B7F1DC'></sup></strike><code id='45D2B7F1DC'></code></optgroup>
        1. <b id='45D2B7F1DC'><label id='45D2B7F1DC'><select id='45D2B7F1DC'><dt id='45D2B7F1DC'><span id='45D2B7F1DC'></span></dt></select></label></b><u id='45D2B7F1DC'></u>
          <i id='45D2B7F1DC'><strike id='45D2B7F1DC'><tt id='45D2B7F1DC'><pre id='45D2B7F1DC'></pre></tt></strike></i>

          
          WSS
          Alastair Grant/AP

          LONDON — AstraZeneca said Friday an experimental drug tamped down the progression of a certain type of breast cancer in a Phase 3 trial, a win for the company after the same drug produced underwhelming results in a lung cancer trial over the summer.

          The drug, called datopotamab deruxtecan or Dato-DXd for short, succeeded on one of its primary endpoints of improving progression-free survival compared to chemotherapy in certain breast cancer patients who had previously been treated with other therapies.

          advertisement

          AstraZeneca, which is developing Dato-DXd with partner Daiichi Sankyo, said that the data for the other primary endpoint of overall survival were not “mature” as of this interim analysis, but that there was a positive trend. The trial is continuing.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          Wikipedia